ACADIA PHARMACEUTICALS INC
ACADNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $1.07B | $957.8M | $726.4M | $517.2M | $484.1M | $441.8M |
| Operating income | $104.8M | $230.8M | −$73.4M | −$223.6M | −$170.4M | −$286.6M |
| Net income | $391.0M | $226.5M | −$61.3M | −$216.0M | −$167.9M | −$88.0M |
| Total assets | $1.56B | $1.19B | $749.0M | $587.8M | $700.1M | $782.6M |
| Total liabilities | $336.8M | $455.0M | $317.2M | $187.4M | $159.2M | $155.6M |
| Equity | $1.23B | $732.8M | $431.8M | $400.4M | $540.9M | $627.0M |
| EPS (diluted) | $2.30 | $1.36 | $-0.37 | $-1.34 | $-1.05 | $-1.79 |
| Shares out. | 166.8M | 164.8M | 162.2M | 161.2M | 160.0M | 155.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 9.8%
- Net margin
- 36.5%
- Return on equity
- 31.9%
- Return on assets
- 25.0%
- Return on capital (ROCE)
- 8.1%
- Liabilities / assets
- 21.5%
- Debt / equity
- 0.27×
- Book value / share
- $7.36
- Revenue growth (YoY)
- 11.9%
- Net income growth (YoY)
- 72.7%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 3.79safe
- Accruals / assets
- 18.0%high accruals
- Beneish M-Score
- -1.00elevated
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 warning● 6 good- High accruals — earnings-quality risk
- Beneish M-Score elevated — earnings-manipulation screen flag
- Operating margin is positive
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Active Not Recruitingreadout ~2025-10Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
- Phase 2Recruitingreadout ~2027-08ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
- Phase 2/3Recruitingreadout ~2028-01ACP-204 in Adults With Alzheimer's Disease Psychosis
- Phase 2Recruitingreadout ~2028-02Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
- Phase 3Enrolling By Invitationreadout ~2029-02Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
- Phase 3Enrolling By Invitationreadout ~2029-04ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
- Phase 3Enrolling By Invitationreadout ~2029-05OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Vanguard Portfolio Management LlcPassive (13G)Apr 28, 2026
- Vanguard Group IncPassive (13G)Mar 26, 2026
- Baker Bros. Advisors LpActivist (13D)Feb 26, 2026
- Rtw Investments, LpPassive (13G)Nov 14, 2025
- Blackrock, Inc.Passive (13G)Feb 7, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 11.4M | 5.9 | +2.4% |
| Apr 30, 2026 | 11.2M | 5.9 | +1.6% |
| Apr 15, 2026 | 11.0M | 7.4 | +3.2% |
| Mar 31, 2026 | 10.6M | 4.9 | +23.4% |
| Mar 13, 2026 | 8.6M | 5.0 | -9.1% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer change · Shareholder voteMay 29, 2026
- Results of operationsMay 6, 2026
- Director / officer change · Regulation FD disclosureMay 1, 2026
- Director / officer changeMar 5, 2026
- Results of operationsFeb 25, 2026
- Results of operations · Regulation FD disclosureJan 13, 2026
- Results of operationsNov 5, 2025
- Director / officer changeNov 3, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.